Turtle Creek Wealth Advisors LLC Has $5.41 Million Position in Zoetis Inc. (NYSE:ZTS)

Turtle Creek Wealth Advisors LLC increased its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 71.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,849 shares of the company's stock after acquiring an additional 13,718 shares during the quarter. Turtle Creek Wealth Advisors LLC's holdings in Zoetis were worth $5,409,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of ZTS. Brighton Jones LLC grew its position in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after buying an additional 2,978 shares in the last quarter. Bank Pictet & Cie Europe AG lifted its position in shares of Zoetis by 5.4% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 419,530 shares of the company's stock worth $68,354,000 after acquiring an additional 21,470 shares during the period. Proficio Capital Partners LLC grew its holdings in shares of Zoetis by 61.0% during the 4th quarter. Proficio Capital Partners LLC now owns 3,053 shares of the company's stock worth $497,000 after purchasing an additional 1,157 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $8,710,000. Finally, Intact Investment Management Inc. bought a new stake in shares of Zoetis during the fourth quarter valued at approximately $65,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president owned 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on ZTS. UBS Group lowered their target price on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus lowered Zoetis from a "buy" rating to a "hold" rating and lowered their price objective for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, Piper Sandler raised their target price on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $212.13.

Zoetis Price Performance

NYSE ZTS traded up $0.72 during trading hours on Monday, reaching $155.68. 1,986,473 shares of the company's stock were exchanged, compared to its average volume of 3,011,381. The firm has a fifty day moving average of $161.32 and a 200-day moving average of $161.82. The stock has a market cap of $69.31 billion, a PE ratio of 27.95, a price-to-earnings-growth ratio of 2.57 and a beta of 0.91. The company has a current ratio of 1.74, a quick ratio of 1.04 and a debt-to-equity ratio of 1.12. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter last year, the company posted $1.38 EPS. The company's quarterly revenue was up 1.4% compared to the same quarter last year. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.28%. Zoetis's dividend payout ratio (DPR) is currently 35.91%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.